FDA Issues Complete Response Letter for Bitopertin NDA, Citing Lack of Clinical Benefit Association

summarizeSummary

Disc Medicine received a Complete Response Letter from the FDA for its New Drug Application for bitopertin, delaying approval due to insufficient evidence linking the surrogate endpoint to clinical benefit. The company will now rely on its ongoing Phase 3 APOLLO study for potential traditional approval, with results expected in Q4 2026.

check_boxKey Events

• FDA Issues Complete Response Letter (CRL)

  The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP).

• Lack of Clinical Benefit Association Cited

  The FDA acknowledged that bitopertin significantly lowers PPIX (a surrogate endpoint) but concluded that submitted trials (AURORA and BEACON) did not show evidence of association between PPIX changes and sunlight exposure-based clinical endpoints.

• Reliance on Ongoing Phase 3 APOLLO Study

  The FDA indicated that results from the ongoing Phase 3 APOLLO study could serve as evidence to support traditional approval, with topline data anticipated in Q4 2026.

• Delayed Approval Timeline

  The CRL will delay potential approval, with a response to the CRL planned after APOLLO completion and an updated FDA decision expected by mid-2027.

auto_awesomeAnalysis

The FDA's Complete Response Letter (CRL) for bitopertin's New Drug Application represents a significant setback for Disc Medicine, delaying the potential market entry of a key pipeline asset. While the FDA acknowledged bitopertin's ability to lower PPIX, the lack of demonstrated association between this surrogate endpoint and clinical benefit in the submitted trials (AURORA and BEACON) is a critical issue. The path forward now relies on the ongoing Phase 3 APOLLO study, pushing a potential FDA decision to mid-2027. This introduces substantial uncertainty and extends the timeline for commercialization, which will likely weigh on investor sentiment. The company's strong cash position, previously disclosed on January 12, 2026, provides a financial buffer to continue development through this extended period.